Arndt Vogel/X
Jun 1, 2025, 00:32
Arndt Vogel: 1st line encorafenib + cetuximab + mFOLFOX6 vs SOC in BRAF V600E-mCRC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, posted on X:
“1st line encorafenib + cetuximab + mFOLFOX6 vs SOC in BRAF V600E-mCRC
BREAKWATER: PFS + updated OS
ASCO25
ORR 65 vs 37 vs 43 %
mPFS 12.8 vs 7.1 vs 6.9 mo
mOS 30.3 vs 15.1 vs 19.1 mo
AE ≥3 76% vs 58 vs 15.7%
Really effective, new SOC in 1st line.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49